EVERSANA

Some of EVERSANA’s industry experts recently conducted research that highlights the significant impact of targeted therapies for myelodysplastic syndromes (MDS), a challenging hematologic malignancy. Some key insights include that targeted therapies can reduce 12-month mortality rates by 46.5% for MDS patients and only 9% of biomarker-positive MDS patients currently receive these therapies, highlighting critical disparities in care. By addressing these gaps, we can ensure eligible patients benefit from these innovative treatments. bridging the divide between groundbreaking science and patient care. Learn more: https://ow.ly/90IW50UoqPY

What’s shaping the future of healthcare in 2025 and beyond? Access Frontiers Health 2024: 24 Key Takeaways in Health Innovation, the exclusive booklet highlighting the ideas and ingenuity that made this year’s global conference a success. Readers can expect: • 24 powerful takeaways offering compelling insights and expert analysis • Top-notch learnings from Frontiers Health’s global speakers in Berlin • Key topics shaping the future of health Discover more from the booklet, created in partnership with pharmaphorum: https://lnkd.in/d-dEu_Gw #HealthInnovation #DigitalHealth #FutureHealth #AI #HealthEquity #PrecisionMedicine #DTx #VirtualCare #WomensHealth

When launching rare disease therapies, precision and reliability in distribution are critical. Manufacturers need a partner with proven capabilities to ensure therapies reach patients safely and on time. EVERSANA’s expertise in inventory accuracy, cold chain logistics and seamless shipments across all 50 U.S. states and territories ensures therapies are handled with the utmost care. With preeminent dispensing and on-time shipment accuracy, we deliver on your promise to patients. Learn more about how our precision helps drive better outcomes: https://ow.ly/IY4o50UsEfX

For patients with metastatic castration-resistant prostate cancer (mCRPC), quality of life (QoL) is a key focus. Our new blog explores the significance of QoL metrics in the development, approval, and reimbursement of cancer therapies. Learn about the findings from EVERSANA's systematic literature review and meta-analysis, conducted with Pfizer, and how these insights can inform better healthcare decisions and improve patient outcomes. Read the blog: https://lnkd.in/gfNMfwcG Rhett Figliuzzi , Samantha Craigie , Sarah Walsh , Imtiaz Samjoo #ProstateCancer #mCRPC #QualityOfLife

Scott Snyder discusses the current relationship between pharma and AI, highlighting the challenges and opportunities in AI adoption. Despite high interest, only 11% of companies are deploying Generative AI at scale. Discover why and what the future holds for AI in Pharmaceutical Executive: https://lnkd.in/gW3cjrHj #AI #Pharma #Innovation #DigitalTransformation

Kevin O'Meara shares his thoughts on the ever-changing landscape of direct-to-patient models and the complexities of today’s healthcare ecosystem in a recent interview with Pharmaceutical Commerce Magazine Commerce. Discover Kevin’s insights on how these approaches aim to improve patient access to therapies. Watch the full interview here: https://lnkd.in/gFWX4dr9 #HealthcareInnovation #PatientCentricity #DTP

ConTIPI Medical Ltd and EVERSANA are excited to see ProVate's positive impact on women's health. This non-surgical, disposable device for pelvic organ prolapse (POP) is empowering women with an easy-to-use, at-home solution. Our CEO Jim Lang shares his enthusiasm for this innovative product and its potential to transform lives. Discover more: https://lnkd.in/gSVRJcER #WomensHealth #MedicalInnovation #ProVate

Attending Informa’s Biotech Showcase? Join Faruk Abdullah and Sharon Cunningham for a fireside chat about how to leverage early commercial development and understand the pre-revenue milestones that can support your capital raise. https://ow.ly/LaPM50Uf6XU #Partnerships #Commercialization #JPM2025

EVERSANA’s Specialty Pharmacy has received two prestigious designations: the URAC Specialty Pharmacy Version 5.0 Accreditation and the URAC Rare Disease Center of Excellence 3.0 Certification. These accolades highlight our dedication to delivering superior specialty pharmacy services and exceptional care for patients, especially those impacted with rare diseases. Read the full press release: https://lnkd.in/dwQ_jqKU #SpecialtyPharmacy #RareDisease #HealthcareExcellence #PatientCare URAC

In this season of gratitude, we’re especially grateful for our global team. They are relentless in their pursuit of improving our world’s healthcare landscape. From identifying undiagnosed and misdiagnosed patients to bringing new therapies to the attention of healthcare providers and patients alike, their innovation inspires us. Incredible people do incredible things, and EVERSANA is unabashedly full of them. Recently, we asked our inspiring team two simple questions about why they chose to vote us a #GreatPlaceToWork: 1. How does our unique culture fuel you to push the boundaries? 2. What motivates you to bring everything you have to work each day? Their responses touched our hearts and our minds. 🔗 Read Now: https://ow.ly/U1Lg50UpcX0 Our heartfelt thanks to the following employees for sharing their perspectives: • Adam Hardy PhD • Anil Pandey • Brad Hollen • Chaitrali Rai • Chris Lagoeiro • Elisabetta Ravot, Ph.D. • Francesca Filippucci • Haelim Choi • Jessica Creed • John Kenny, PhD • Kamalpreet Mann • Mohseen Mulla • Minh-Long Thai • Srikant Panigrahy • Wojciech Kędzierski • Yasuyo Tanaka #GPTWCertified #EVERSANA #WorkCulture #WeAreEVERSANA Great Place To Work US Great Place to Work® Canada Great Place to Work® Institute (India) Great Place to Work® Ireland Great Place To Work UK Great Place To Work® Polska Great Place To Work® Singapore 働きがいのある会社研究所／Great Place To Work® Japan Great Place to Work® Italia